NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust growth throughout the 2016-2026 forecast period. The biggest driver of market sales growth will be the continued uptake and anticipated label expansions of immune checkpoint inhibitors. Merck & ;s Keytruda became the first immune checkpoint inhibitor to receive approval for first-line NSCLC and is anticipated to generate significant sales in this setting. EGFR and ALK inhibitor drug classes will also contribute to market growth following the first-line label expansions of Tagrisso and Alecensa, respectively. Several new therapies will gain approvals within the forecast period, from four different drug classes, resulting in increased therapy options and a highly competitive market. 
Questions Answered 

  • How large are the drug-treatable NSCLC populations and how will the drug-treatment rates change over time? 
  • What is the current state of treatment in NSCLC ? What are interviewed experts’ insights on current treatment options?  What clinical needs remain unfulfilled? 
  • How will different immune checkpoint inhibitor regimens compete in the first-line metastatic NSCLC setting? What will patient share dynamics look like in high PD-L1  ( TPS  ≥50%) and negative/low- PD-L1 patient segments? 
  • What will be the therapy options for EGFR - and ALK -positive patients following progression on first-line Tagrisso and Alecensa, respectively? 
  • What pipeline products are most promising, and what sales/uptake could they secure in NSCLC ? What therapies of note are progressing in earlier phases? 
  • What are the drivers and constraints in the NSCLC market, and how will the market evolve over the forecast period? 


Product Description 
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. 


Related Reports

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung can...

View Details

Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint i...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details

Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018

The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies i...

View Details